Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)

Christopher A. Yasenchak(Willamette Valley Cancer Institute and Research Center), J.T. Beck(Highlands Oncology Group), Vivian Jean M. Cline(Texas Oncology), Jerome H. Goldschmidt, Rodolfo Bordoni(Georgia Cancer Specialists), Jingmin Liu(Southern Medical University), Dipti Patel‐Donnelly(Orthopaedic Research of Virginia), Timothy Larson(The US Oncology Network), Ralph V. Boccia(Center for Cancer and Blood Disorders), Adrija Mamidipalli(Seagen (United States))
Blood
November 15, 2022
10.1182/blood-2022-156567
Cited by 2

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial
|The Lancet Oncology|2013|387
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|386